The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 18, 2022

Filed:

Apr. 09, 2020
Applicant:

Omnicyte, New York, NY (US);

Inventors:

Peter Leonardi, New York, NY (US);

Elin Martina Pola, Agunnaryd, SE;

Jeffrey Babad, Mamaroneck, NY (US);

Assignee:

OMNICYTE, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 7/00 (2006.01); A61K 39/00 (2006.01); C07K 14/005 (2006.01); A61K 39/385 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 39/001188 (2018.08); A61K 39/385 (2013.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); A61K 2039/6075 (2013.01); C07K 2319/00 (2013.01); C12N 2770/36134 (2013.01);
Abstract

The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.


Find Patent Forward Citations

Loading…